It has been well established that vascular endothelial growth factor (VEGF) inhibition is Associated with the following when given intravenously for cancer [1-3].

• A higher risk of proteinuria (abnormal protein leakage in the urine)
• Worsening high blood pressure
• Development of glomerular disease (auto immune kidney disease)
• Thrombotic microangiopathy (vascular auto immune kidney disease)
• Venous thromboembolism [DVT/PE] (clots in leg veins, and lungs)
• Increased risk of heart attacks and strokes;

Our group at the University of California Irvine has detected, publicized, and published 14 cases of glomerular disease, proteinuria exacerbation, poorly controlled hypertension after the use of intravitreal VEGF inhibition [4-14].. Prior publicization involving multiple publications and raising awareness on social media To date there are 32 reported cases and multiple positive studies demonstrating increased risk of the same type of kidney and systemic effects [5-9, 12-28].

---

We have established this website as a registry to develop a way to more easily detect cases of suspected kidney injury, blood pressure worsening, protein leakage worsening, or the development of auto immune kidney disease (glomerular disease) as well as raising awareness on this important rising toxicity concern.